Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply
- PMID: 37434464
- DOI: 10.1111/jvh.13871
Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply
Comment on
-
Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals.J Viral Hepat. 2023 Jun;30(6):530-539. doi: 10.1111/jvh.13818. Epub 2023 Feb 19. J Viral Hepat. 2023. PMID: 36773329
-
Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).J Viral Hepat. 2023 Nov;30(11):897-900. doi: 10.1111/jvh.13865. Epub 2023 Jun 26. J Viral Hepat. 2023. PMID: 37357886 No abstract available.
References
REFERENCES
-
- Barré T, Zucman D, Marcellin F, et al. Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH). J Viral Hepat. 2023. Online ahead of print. doi:10.1111/jvh.13865
-
- Rossotti R, Merli M, Baiguera C, et al. Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals. J Viral Hepat. 2023;30:530-539.
-
- Luz-Vega M, Azevedo-Silva J, Fernandes JC. Beyond pain relief: a review on cannabidiol potential in medical therapies. Pharmaceuticals. 2023;16:155.
-
- Kozela E, Juknat A, Gao F, Kaushansky N, Coppola G, Vogel Z. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. J Neuroinflammation. 2016;13:136.
-
- Jean-Gilles L, Braitch M, Latif ML, et al. Effects of pro-inflammatory cytokines on cannabinoid CB 1 and CB 2 receptors in immune cells. Acta Physiol. 2015;214:63-74.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials